Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9571783 | 0.80 | LMNA (0.32) | KDM4CALDH1A1CYP11B1CYP11B2LMNA | |
| SCHEMBL9571793 | 0.78 | ALDH1A1 (0.32) | ALDH1A1CYP11B1CYP11B2LMNAKDM4E | |
| SCHEMBL9655749 | 0.78 | RAB9A (0.46) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL9655756 | 0.78 | RAB9A (0.46) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL10439558 | 0.78 | CYP1A2 (0.44) | ALDH1A1CYP11B1CYP11B2LMNAKDM4E | |
| SCHEMBL949247 | 0.77 | CYP11B1 (0.34) | ALDH1A1CYP11B1CYP11B2LMNACYP2A6 | |
| SCHEMBL7319467 | 0.77 | NR4A2 (0.38) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL7325023 | 0.77 | NR4A2 (0.38) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL2233946 | 0.76 | KCNN4 (0.36) | ALDH1A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL643163 | 0.75 | CYP11B1 (0.37) | ALDH1A1CYP11B1CYP11B2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-1471056-B1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-2275411-A2 | Reformatsky Reagent in Stable Form and Process for Producing the Same | Takeda Pharmaceutical Company Limited (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-4859662-A | Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating 5-HT function disturbances | GLAXO GROUP LIMITED (GB) | 1989-08-22 | — | — | US | disclosed |
| EP-0327307-A2 | Tricyclic ketone derivatives having a 5-HT3 antagonist activity | GLAXO GROUP LIMITED (GB) | 1989-08-09 | — | — | EP | disclosed |
| EP-0317088-A1 | Ketone derivatives | GLAXO GROUP LIMITED (GB) | 1989-05-24 | — | — | EP | disclosed |
| US-4822881-A | PSYCHOTIC DISORDERS, ANXIETY, NAUSEA, VOMITING | GLAXO GROUP LIMITED | 1989-04-18 | — | — | US | disclosed |
| US-4814343-A | ANTIISCHEMIC | U C B, S.A. (BE) | 1989-03-21 | — | — | US | disclosed |
| US-4808581-A | ANXIOLYTIC, ANTIEMETIC, TREATMENT OF PSYCHOLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1989-02-28 | — | — | US | disclosed |
| EP-0291172-A1 | Ketone derivatives | GLAXO GROUP LIMITED (GB) | 1988-11-17 | — | — | EP | disclosed |
| EP-0269599-A2 | Substituted 1H-imidazoles | U C B, S.A. (BE) | 1988-06-01 | — | — | EP | disclosed |
| EP-0242973-A1 | Indole derivatives, method for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | KDM4C 1565/4885ALDH1A1 1252/4885CYP11B1 21/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | KDM4C 1880/4885ALDH1A1 2316/4885CYP11B1 25/4885 |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | KDM4C 707/4885ALDH1A1 440/4885CYP11B1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.